New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
10:29 EDTAUXLAuxilium generic Testim strategy defended at UBS
UBS believes Auxilium shares are lower as investors assume Upsher’s generic version of Testim could be approved as an AB-rated generic, but the firm noted that is not yet the case. UBS thinks Auxilium shares will recover as investors recognize that the generic strategy should maximize Testim sales over the medium term and maintains its Buy rating and $31 price target on the stock.
News For AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:13 EDTAUXLBioSpecifics announces FDA approval of sBLA for XIAFLEX
Subscribe for More Information
October 20, 2014
17:33 EDTAUXLAuxilium announces XIAFLEX approved for treatment of up to two DC joints
Subscribe for More Information
October 13, 2014
06:41 EDTAUXLEndo upgraded to Hold from Sell at Cantor
Subscribe for More Information
October 10, 2014
11:18 EDTAUXLOptions with decreasing implied volatility
Subscribe for More Information
10:01 EDTAUXLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:35 EDTAUXLAuxilium downgraded to Neutral from Buy at MKM Partners
Subscribe for More Information
05:50 EDTAUXLEndo upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Endo (ENDP) to Overweight with an $84 price target citing an improved asset base following the takeover of Auxilium (AUXL).
05:47 EDTAUXLAuxilium downgraded to Neutral from Buy at Mizuho
Mizuho downgraded Auxilium (AUXL) to Neutral following the company's agreement to be acquired by Endo (ENDP). The firm expects shareholders to approve the deal and does not expect a competing bid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use